Hisun’s Biosimilar Enbrel To Get CFDA Site Inspection
This article was originally published in PharmAsia News
Executive Summary
The China FDA’s website indicates that Hisun Pharma’s “AnBaiNuo”, a biosimilar version of Amgen and Pfizer’s Enbrel (etanercept), will be on-site inspected within this month for drug registration purposes.